Skip to main content

Clinical and pathological significance of N-Myc downstream-regulated gene 2 (NDRG2) in diverse human cancers

Apoptosis volume 21, pages 675–682 (2016)Cite this article

Abstract

Human N-Myc downstream-regulated gene 2 (NDRG2), located at chromosome 14q11.2, has been reported to be down-regulated and associated with the progression and prognosis of diverse cancers. Collectively, previous studies suggest that NDRG2 functions as a candidate tumor-suppressor gene; thus, up-regulation of NDRG2 protein might act as a promising therapeutic strategy for malignant tumors. The aim of this review was to comprehensively present the clinical and pathological significance of NDRG2 in human cancers.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Qu X, Zhai Y, Wei H et al (2002) Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem 229:35–44

    CAS  Article  PubMed  Google Scholar 

  2. Melotte V, Qu X, Ongenaert M et al (2010) The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB J 24:4153–4166

    CAS  Article  PubMed  Google Scholar 

  3. Fang BA, Kovacevic Z, Park KC et al (2014) Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy. Biochim Biophys Acta 1845:1–19

    CAS  Article  PubMed  Google Scholar 

  4. Zhou RH, Kokame K, Tsukamoto Y, Yutani C, Kato H, Miyata T (2001) Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics 73:86–97

    CAS  Article  PubMed  Google Scholar 

  5. Shaw E, McCue LA, Lawrence CE, Dordick JS (2002) Identification of a novel class in the alpha/beta hydrolase fold superfamily: the N-myc differentiation-related proteins. Proteins 47:163–168

    CAS  Article  PubMed  Google Scholar 

  6. Yao L, Zhang J, Liu X (2008) NDRG2: a Myc-repressed gene involved in cancer and cell stress. Acta Biochim Biophys Sin (Shanghai) 40:625–635

    CAS  Article  Google Scholar 

  7. Kitowska A, Pawelczyk T (2010) N-myc downstream regulated 1 gene and its place in the cellular machinery. Acta Biochim Pol 57:15–21

    CAS  PubMed  Google Scholar 

  8. Nichols NR (2003) Ndrg2, a novel gene regulated by adrenal steroids and antidepressants, is highly expressed in astrocytes. Ann N Y Acad Sci 1007:349–356

    CAS  Article  PubMed  Google Scholar 

  9. Kovacevic Z, Richardson DR (2006) The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 27:2355–2366

    CAS  Article  PubMed  Google Scholar 

  10. Yang X, An L, Li X (2013) NDRG3 and NDRG4, two novel tumor-related genes. Biomed Pharmacother 67:681–684

    CAS  Article  PubMed  Google Scholar 

  11. Melotte V, Lentjes MH, van den Bosch SM et al (2009) N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst 101:916–927

    CAS  Article  PubMed  Google Scholar 

  12. Wang W, Li Y, Hong A, Wang J, Lin B, Li R (2009) NDRG3 is an androgen regulated and prostate enriched gene that promotes in vitro and in vivo prostate cancer cell growth. Int J Cancer 124:521–530

    CAS  Article  PubMed  Google Scholar 

  13. Takahashi K, Yamada M, Ohata H, Honda K (2005) Ndrg2 promotes neurite outgrowth of NGF-differentiated PC12 cells. Neurosci Lett 388:157–162

    CAS  Article  PubMed  Google Scholar 

  14. Wang L, Liu N, Yao L et al (2008) NDRG2 is a new HIF-1 target gene necessary for hypoxia-induced apoptosis in A549 cells. Cell Physiol Biochem 21:239–250

    CAS  Article  PubMed  Google Scholar 

  15. Shen L, Liu X, Hou W et al (2010) NDRG2 is highly expressed in pancreatic beta cells and involved in protection against lipotoxicity. Cell Mol Life Sci 67:1371–1381

    CAS  Article  PubMed  Google Scholar 

  16. Li Y, Liu C, Hou W et al (2014) Retrograde ductal administration of the adenovirus-mediated NDRG2 gene leads to improved sialaden hypofunction in estrogen-deficient rats. Mol Ther 22:908–918

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Li Y, Yang J, Li S et al (2011) N-myc downstream-regulated gene 2, a novel estrogen-targeted gene, is involved in the regulation of Na+/K+-ATPase. J Biol Chem 286:32289–32299

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. Hu W, Fan C, Jiang P et al (2015) Emerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancer. Oncotarget 7:209–223

    PubMed Central  Google Scholar 

  19. Cao W, Zhang JL, Feng DY et al (2014) The effect of adenovirus-conjugated NDRG2 on p53-mediated apoptosis of hepatocarcinoma cells through attenuation of nucleotide excision repair capacity. Biomaterials 35:993–1003

    CAS  Article  PubMed  Google Scholar 

  20. Jong WM, Leemans JC, Weber NC et al (2014) Nlrp3 plays no role in acute cardiac infarction due to low cardiac expression. Int J Cardiol 177:41–43

    Article  PubMed  Google Scholar 

  21. Ren GF, Tang L, Yang AQ, Jiang WW, Huang YM (2014) Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy. Histol Histopathol 29:535–542

    CAS  PubMed  Google Scholar 

  22. Zhang ZG, Li G, Feng DY et al (2014) Overexpression of NDRG2 can inhibit neuroblastoma cell proliferation through negative regulation by CYR61. Asian Pac J Cancer Prev 15:239–244

    Article  PubMed  Google Scholar 

  23. Shi H, Li N, Li S et al (2010) Expression of NDRG2 in esophageal squamous cell carcinoma. Cancer Sci 101:1292–1299

    CAS  Article  PubMed  Google Scholar 

  24. Cao W, Yu G, Lu Q, Zhang J (2013) Low expression of N-myc downstream-regulated gene 2 in oesophageal squamous cell carcinoma correlates with a poor prognosis. BMC Cancer 13:305

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. Plummer M, Franceschi S, Vignat J, Forman D, de Martel C (2015) Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 136:487–490

    CAS  Article  PubMed  Google Scholar 

  26. Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128

    Article  PubMed  Google Scholar 

  27. Choi SC, Yoon SR, Park YP et al (2007) Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med 39:705–714

    CAS  Article  PubMed  Google Scholar 

  28. Chang X, Li Z, Ma J et al (2013) DNA methylation of NDRG2 in gastric cancer and its clinical significance. Dig Dis Sci 58:715–723

    CAS  Article  PubMed  Google Scholar 

  29. Tao Y, Guo Y, Liu W et al (2013) AKT inhibitor suppresses hyperthermia-induced Ndrg2 phosphorylation in gastric cancer cells. Braz J Med Biol Res 46:394–404

    Article  PubMed  PubMed Central  Google Scholar 

  30. Merika E, Saif MW, Katz A, Syrigos K, Morse M (2010) Review. Colon cancer vaccines: an update. In Vivo 24:607–628

    CAS  PubMed  Google Scholar 

  31. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108

    Article  PubMed  Google Scholar 

  32. Simons CC, Schouten LJ, Godschalk R et al (2015) Body size, physical activity, genetic variants in the insulin-like growth factor pathway and colorectal cancer risk. Carcinogenesis 36:971–981

    CAS  Article  PubMed  Google Scholar 

  33. Chu D, Zhang Z, Li Y, Wu L, Zhang J, Wang W (2011) Prediction of colorectal cancer relapse and prognosis by tissue mRNA levels of NDRG2. Mol Cancer Ther 10:47–56

    CAS  Article  PubMed  Google Scholar 

  34. Feng L, Xie Y, Zhang H, Wu Y (2011) Down-regulation of NDRG2 gene expression in human colorectal cancer involves promoter methylation and microRNA-650. Biochem Biophys Res Commun 406:534–538

    CAS  Article  PubMed  Google Scholar 

  35. Kim YJ, Yoon SY, Kim JT et al (2009) NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma. Carcinogenesis 30:598–605

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  36. Lorentzen A, Vogel LK, Lewinsky RH et al (2007) Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer 7:192

    Article  PubMed  PubMed Central  Google Scholar 

  37. Shi H, Jin H, Chu D et al (2009) Suppression of N-myc downstream-regulated gene 2 is associated with induction of Myc in colorectal cancer and correlates closely with differentiation. Biol Pharm Bull 32:968–975

    CAS  Article  PubMed  Google Scholar 

  38. Kim YJ, Kang HB, Yim HS, Kim JH, Kim JW (2013) NDRG2 positively regulates E-cadherin expression and prolongs overall survival in colon cancer patients. Oncol Rep 30:1890–1898

    CAS  PubMed  Google Scholar 

  39. Kim YJ, Yoon SY, Kim JT et al (2009) NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells. Int J Cancer 124:7–15

    CAS  Article  PubMed  Google Scholar 

  40. Mittal S, El-Serag HB (2013) Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 47(Suppl):S2–S6

    Article  PubMed  PubMed Central  Google Scholar 

  41. de Martel C, Ferlay J, Franceschi S et al (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13:607–615

    Article  PubMed  Google Scholar 

  42. Deuschle U, Schuler J, Schulz A et al (2012) FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS One 7:e43044

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  43. Hu XL, Liu XP, Lin SX et al (2004) NDRG2 expression and mutation in human liver and pancreatic cancers. World J Gastroenterol 10:3518–3521

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  44. Lee DC, Kang YK, Kim WH et al (2008) Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res 68:4210–4220

    CAS  Article  PubMed  Google Scholar 

  45. Zheng J, Li Y, Yang J et al (2011) NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression. BMC Cancer 11(251):251–259

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. Guo Y, Ma J, Wu L et al (2013) Hyperthermia-induced NDRG2 upregulation inhibits the invasion of human hepatocellular carcinoma via suppressing ERK1/2 signaling pathway. PLoS ONE 8:e61079

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  47. Yamamura A, Miura K, Karasawa H et al (2013) Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer. Biochem Biophys Res Commun 441:102–107

    CAS  Article  PubMed  Google Scholar 

  48. Kapoor VK, McMichael AJ (2003) Gallbladder cancer: an ‘Indian’ disease. Natl Med J India 16:209–213

    CAS  PubMed  Google Scholar 

  49. Lee DG, Lee SH, Kim JS et al (2015) Loss of NDRG2 promotes epithelial-mesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression. J Hepatol 63:1429–1439

    CAS  Article  PubMed  Google Scholar 

  50. Song SP, Zhang SB, Liu R et al (2012) NDRG2 down-regulation and CD24 up-regulation promote tumor aggravation and poor survival in patients with gallbladder carcinoma. Med Oncol 29:1879–1885

    CAS  Article  PubMed  Google Scholar 

  51. Mamelak AN, Jacoby DB (2007) Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv 4:175–186

    CAS  Article  PubMed  Google Scholar 

  52. Deng Y, Yao L, Chau L et al (2003) N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer 106:342–347

    CAS  Article  PubMed  Google Scholar 

  53. Skiriute D, Vaitkiene P, Asmoniene V, Steponaitis G, Deltuva VP, Tamasauskas A (2013) Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma. J Neurooncol 113:441–449

    CAS  Article  PubMed  Google Scholar 

  54. Li W, Chu D, Chu X et al (2011) Decreased expression of NDRG2 is related to poor overall survival in patients with glioma. J Clin Neurosci 18:1534–1537

    CAS  Article  PubMed  Google Scholar 

  55. Zhou B, Tang Z, Deng Y et al (2014) Tumor suppressor candidate gene, NDRG2 is frequently inactivated in human glioblastoma multiforme. Mol Med Rep 10:891–896

    CAS  PubMed  Google Scholar 

  56. Tepel M, Roerig P, Wolter M et al (2008) Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer 123:2080–2086

    CAS  Article  PubMed  Google Scholar 

  57. Li L, Wang J, Shen X et al (2011) Expression and prognostic value of NDRG2 in human astrocytomas. J Neurol Sci 308:77–82

    CAS  Article  PubMed  Google Scholar 

  58. Skiriute D, Tamasauskas S, Asmoniene V et al (2011) Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas. J Neurooncol 102:89–94

    CAS  Article  PubMed  Google Scholar 

  59. Lusis EA, Watson MA, Chicoine MR et al (2005) Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 65:7121–7126

    CAS  Article  PubMed  Google Scholar 

  60. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369:2106–2120

    CAS  Article  PubMed  Google Scholar 

  61. Liang ZL, Kang K, Yoon S et al (2012) NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy. Ann Surg Oncol 19:2763–2772

    Article  PubMed  Google Scholar 

  62. Ma J, Jin H, Wang H et al (2008) Expression of NDRG2 in clear cell renal cell carcinoma. Biol Pharm Bull 31:1316–1320

    CAS  Article  PubMed  Google Scholar 

  63. Ma JJ, Kong LM, Liao CG, Jiang X, Wang Y, Bao TY (2012) Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion. Med Oncol 29:3306–3313

    CAS  Article  PubMed  Google Scholar 

  64. Ma JJ, Liao CG, Jiang X, Zhao HD, Yao LB, Bao TY (2010) NDRG2 suppresses the proliferation of clear cell renal cell carcinoma cell A-498. J Exp Clin Cancer Res 29:103

    Article  PubMed  PubMed Central  Google Scholar 

  65. Yu C, Wu G, Dang N et al (2011) Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma. Cancer Biol Ther 12:304–313

    CAS  Article  PubMed  Google Scholar 

  66. Gao L, Wu GJ, Liu XW et al (2011) Suppression of invasion and metastasis of prostate cancer cells by overexpression of NDRG2 gene. Cancer Lett 310:94–100

    CAS  Article  PubMed  Google Scholar 

  67. Li R, Yu C, Jiang F et al (2013) Overexpression of N-Myc downstream-regulated gene 2 (NDRG2) regulates the proliferation and invasion of bladder cancer cells in vitro and in vivo. PLoS One 8:e76689

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  68. Li SJ, Wang WY, Li B et al (2013) Expression of NDRG2 in human lung cancer and its correlation with prognosis. Med Oncol 30:421

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  69. Wang H, Wang W, Wang X et al (2012) Reduced N-Myc downstream-regulated gene 2 expression is associated with CD24 upregulation and poor prognosis in patients with lung adenocarcinoma. Med Oncol 29:3162–3168

    CAS  Article  PubMed  Google Scholar 

  70. Jeschke J, Van Neste L, Glockner SC et al (2012) Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics 7:701–709

    CAS  Article  PubMed  Google Scholar 

  71. Lorentzen A, Lewinsky RH, Bornholdt J, Vogel LK, Mitchelmore C (2011) Expression profile of the N-myc Downstream Regulated Gene 2 (NDRG2) in human cancers with focus on breast cancer. BMC Cancer 11:14

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  72. Zheng J, Liu Q, Li Y et al (2010) NDRG2 expression regulates CD24 and metastatic potential of breast cancer cells. Asian Pac J Cancer Prev 11:1817–1821

    PubMed  Google Scholar 

  73. Liu J, Zhang J, Wang X et al (2010) HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. Exp Cell Res 316:1985–1993

    CAS  Article  PubMed  Google Scholar 

  74. Zhao H, Zhang J, Lu J et al (2008) Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer 8:303

    Article  PubMed  PubMed Central  Google Scholar 

  75. Kim A, Kim MJ, Yang Y, Kim JW, Yeom YI, Lim JS (2009) Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis 30:927–936

    CAS  Article  PubMed  Google Scholar 

  76. Furuta H, Kondo Y, Nakahata S, Hamasaki M, Sakoda S, Morishita K (2010) NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma. Biochem Biophys Res Commun 391:1785–1791

    CAS  Article  PubMed  Google Scholar 

  77. Tschan MP, Shan D, Laedrach J et al (2010) NDRG1/2 expression is inhibited in primary acute myeloid leukemia. Leuk Res 34:393–398

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81500263) and China Postdoctoral Science Foundation (2015M572681).

Author information

Author notes

    Affiliations

    1. Department of Geriatrics, Xijing Hospital, The Fourth Military Medical University, 127 Changle West Road, Xi’an, 710032, China

      Wei Hu & Jianyuan Gao

    2. Department of Biomedical Engineering, The Fourth Military Medical University, 169 Changle West Road, Xi’an, 710032, China

      Wei Hu, Yang Yang, Tian Li, Jianjun Lv & Weiwei Yao

    3. Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, 1 Xinsi Road, Xi’an, 710038, China

      Chongxi Fan & Zhiqiang Ma

    4. Department of Cardiovascular Surgery, Xijing Hospital, The Fourth Military Medical University, 127 Changle West Road, Xi’an, 710032, China

      Chao Deng

    Authors
    1. Wei Hu
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Yang Yang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Chongxi Fan
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Zhiqiang Ma
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Chao Deng
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Tian Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Jianjun Lv
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Weiwei Yao
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Jianyuan Gao
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Jianyuan Gao.

    Ethics declarations

    Conflict of interest

    The authors declare no competing financial interests.

    Additional information

    Wei Hu, Yang Yang, Chongxi Fan have contributed equally to this work.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Hu, W., Yang, Y., Fan, C. et al. Clinical and pathological significance of N-Myc downstream-regulated gene 2 (NDRG2) in diverse human cancers. Apoptosis 21, 675–682 (2016). https://doi.org/10.1007/s10495-016-1244-3

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s10495-016-1244-3

    Keywords

    • N-Myc downstream-regulated gene 2
    • Cancers
    • Clinical and pathological significance